Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Cellulite Cream

Application Of Innovative Laser Research Could Lead To Earlier Bone Disorder Diagnosis
A new laser technique that could lead to bone disorders being diagnosed earlier is to be tested in a hospital for the first time. The study, which it"s hoped will pave the way for future clinical trials, will apply a revolutionary approach known as SORS (Spatially Offset Raman Spectroscopy), to examine specific substances in non see-through surfaces deeper than has previously been possible, without damaging the surface. The research team hope ultimately that the method can be used both to detect and screen for early signs of diseases such as osteoarthritis and osteoporosis.
generic viagra online
International Groups Express Concern About Cambodian 'AIDS Colony'
In an open letter to Cambodia"s prime minister and health minister, more than 100 international HIV/AIDS advocates and human rights organizations "accused the Cambodian government of herding HIV-affected families into an "AIDS colony" outside the capital, Phnom Penh," the Guardian reports (McCurry, 7/28).
News of the day
Justice Ginsburg Discusses Abortion Rights, Women On Supreme Court In NYT Magazine Interview
In an interview to be published in this weekend"s New York Times Magazine, Supreme Court Justice Ruth Bader Ginsburg discusses the role of female justices on the court, including the effect on issues related to reproductive rights. When asked if "part of a future feminists legal wish list" could include "repositioning Roe [v. Wade] so that the right to abortion is rooted in the constitutional promise of sex equality," Ginsburg replied, "I think it will be." In response to a follow-up question on what Ginsburg would want to see accomplished in future feminist legal agenda, she said, "Reproductive choice has to be straightened out." She later clarified that she meant that the "basic thing is that the government has no business making that choice for any woman." Ginsburg said that there "will never be a woman of means without choice anymore" and that the "states that had changed their abortion laws before Roe (to make abortion legal) are not going to change it back." However, "we have a policy that only affects poor women, and it can never be otherwise, and I don"t know why this hasn"t been said more often," she said. She continued that she was "surprised" by the Supreme Court"s 1980 ruling in Harris v. McRae, which upheld the Hyde Amendment prohibiting states from using federal Medicaid funds to pay for abortion. Ginsburg also discussed state restrictions on abortion rights, such as waiting periods, and other limits to accessing the procedure. She added that the "possibility of stopping a pregnancy very early is significant" and predicted that emergency contraception "will become more accessible and easier to take." Ginsburg said, "So I think the side that wants to take the choice away from women and give it to the state, they"re fighting a losing battle. Time is on the side of change" (Bazelon, New York Times Magazine, 7/12).
Sexual Health

Boston Scientific Data Show Real-World Survival Rates For Implantable Cardiac Device Patients Exceed Rates From Clinical Trials

Boston Scientific Corporation (NYSE: BSX) announced data from its ALTITUDE Clinical Science program that show real-word survival rates for implantable cardiac device patients exceeding rates from clinical trials. ALTITUDE analyzes outcomes data from patients monitored by the LATITUDE(R) Patient Management system. Five-year survival rate data for patients using implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy defibrillators (CRT-Ds) were presented at the Heart Rhythm Society Scientific Sessions in Boston by Leslie Saxon, M.D., F.A.C.C., Chief, Cardiovascular Medicine at the Cardiovascular and Thoracic Institute, University of Southern California, and chairperson of the ALTITUDE physician panel. Boston Scientific has enrolled more than 130,000 patients on the LATITUDE system since its introduction in 2006, making it the most rapidly adopted remote cardiac device monitoring system in the industry(1). The LATITUDE system enables physicians to schedule remote follow-ups of implantable cardiac device patients to monitor specific device information and heart health status. The system can also detect clinical events between scheduled visits and send relevant data directly to physicians. This regular, in-home monitoring offers convenience and peace of mind for patients. Findings presented today from ALTITUDE, which analyzed nearly 86,000 patients monitored by the LATITUDE system, include: -- Five-year survival rates for ICD patients of up to 92 percent -- Five-year survival rates for CRT-D patients of up to 78 percent "In contrast to clinical trials, the ALTITUDE program analyzes device therapy in real-world practice and offers insights into clinical event rates and disease progression for extensive ICD and CRT-D patient populations," said Dr. Saxon. "This observational cohort study represents the largest cardiac device patient cohort to date and clearly shows survival rates exceed those reported in randomized trials." "Boston Scientific is known for excellence in its clinical trials, such as MADIT, MADIT II, COMPANION and MADIT-CRT," said Fred Colen, President, Boston Scientific Cardiac Rhythm Management. "We"re also proud of our significant investment in physician research through post-market analysis. The ALTITUDE Clinical Science program serves physicians by enhancing their understanding of device therapy, outcomes and disease progression in real-world device patients monitored by LATITUDE." Cautionary Statement Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding clinical trials, scientific activities, product performance, competitive offerings and growth investment. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements. Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A- Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file thereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document. (1) Data based on number of patients at three years post-launch. Data on file. Boston Scientific Corporation


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009